Overview
| Name | IsoDDE · aliases: IsoDDE, Isomorphic Labs Drug Design Engine |
|---|---|
| Full name | Isomorphic Labs Drug Design Engine |
| Ambiguous names (not auto-linked) | None |
| Family | Not a family entry. A single internal engine; AlphaFold 3 is its predecessor with its own record |
| Organization | Isomorphic Labs |
| Organization type | AI-native biotech |
| Country | United Kingdom |
| Model class | Co-folding, affinity, cryptic pockets |
| Domain | Structure & co-folding (also: Small molecules, Antibodies) |
| First release | · product update Basis: Official article and Zenodo technical report released the same day source |
| Other milestones | |
| Latest update | · no later event Basis: No technical update found after release No later sourced event found (as of 2026-11-16); the 2026-05 Series B is a corporate event, not a new technical release source The most recent sourced event, not a claim that nothing changed since. |
| Status | Product only, no public artifact · Internal and partner use only; no public code or weights |
| Openness | Code: Closed Weights: Closed Closed internal engine; only the official article and technical report are public |
| Benchmarks reported | 2 counted (self 1, retrospective 1) |
| Wet-lab validation | None recorded |
| Unverified fields | † training_data.a_public, training_data.b_private_licensed, training_data.c_own_wetlab_for_training, benchmarks_reported[0], background.products_partnerships |
| As of | 2026-11-17 |
What it does
An internal drug design engine extending AlphaFold3: co-folding on cases with low similarity to training data, small-molecule binding-affinity prediction and cryptic-pocket identification. Like the open Boltz-2 it covers both structure and affinity, but it is closed and cannot be reproduced externally; it is the main reference point for open AF3 reproductions.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 2 of 2 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 30 PLINDER / PINDER / Runs N' Poses | Developer report, official protocol | — | Self-reported | Tech report claims a large gain in the hardest Runs N' Poses bin; no numeric page †partly verified · evidence |
| 01 CASP | Retrospective dataset use | — | Third-party | CASP16 blind affinity data used post hoc, figure only †partly verified · evidence |
Other evaluations (outside the 44)
- Novel antibody-antigen interface set (Own task set) Self-reported: Own low-similarity antibody interface set compared with AF3 and Boltz-2; vendor-reported
- Affinity comparisons (FEP+, OpenFE, ChEMBL time split) (Comparison against baselines only) Self-reported: Bar charts by protein class, claiming to beat ML and even physics methods; no summary value in the text, and a second-hand figure is not found in official material
- Retrospective cryptic-pocket case (Case study) Self-reported: Retrospective reproduction of a published experimental finding (cereblon case), not new validation
Developers report: clearly better co-folding than AF3 on low-similarity cases, affinity prediction beating all deep-learning methods, and cryptic-pocket identification.
Independent evidence: No independent evidence found. Closed; no third-party reproduction or blind-test result found, and blind rounds such as CASP17 have not reported
Training data
Group in Figure 7: Not disclosed.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Not disclosed | The report only says the cut-off matches AF3 (PDB before 2021-09-30); no dataset list source |
| b. Private or licensed data | Not disclosed | source |
| c. Own wet-lab data used for training | Not disclosed | The report lists no internal experimental data source |
| d. Wet lab used only for validation | No | Only retrospective cases on published structures, no new wet lab source |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: Isomorphic Labs was spun out of Alphabet in 2021, is based in London and is a sister organisation of Google DeepMind, positioned as an AI drug design company; AlphaFold 3 was released jointly by the two.
- Funding: A first external round of $600M (2025-03) and a $2.1B Series B (2026-05), both led by Thrive Capital with Alphabet and GV; valuation undisclosed (company announcements).
- Products and partnerships: Research deals with Eli Lilly and Novartis from 2024-01 (about $82.5M upfront combined, per trade press); the company says new funds go to expanding IsoDDE and moving candidates to the clinic.
- Related models: AlphaFold 3, Boltz-2
Reading notes
- All figures come from the vendor technical report; the official article has none, and there is no third-party reproduction.
- "Beats AF3" is a relative comparison on the hardest similarity bin, not overall Runs N' Poses performance.
- Affinity is the commercially key claim, yet public evidence is comparison charts only, with no citable summary value.
- Being closed, outside checks must wait for partner disclosures or blind-test results.
Caveats
- Vendor-reported, non-peer-reviewed technical report; cannot be reproduced externally.
- The CASP16 affinity use is retrospective, not a competition entry.
- Affinity figures circulating second-hand are not in official material and should not be cited.
- Training data are undisclosed, so generalisation and leakage cannot be assessed externally.
Sources
- IsoDDE technical report (Zenodo) (preprint)
- Official launch article (company blog)
- Series B announcement (company blog)
- First external funding announcement (company blog)
Corrections
None recorded.
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-17.